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Abstract. Background: The role of cellular drug resistance
in childhood acute myeloid leukemia (AML) has not yet been
established. The aim of the study was the analysis of the
clinical value of ex vivo drug resistance in pediatric AML.
Patients and Methods: A cohort of 90 children with de novo
AML were assayed for drug resistance profile by the 3-4,5-
dimethylthiazol-2-yl-2,5-difenyl tetrazolium bromide (MTT)
assay and prognostic model of in vitro drug sensitivity was
analyzed. Results: Children who relapsed during follow-up
showed higher in vitro resistance of leukemic blasts to most
of the drugs tested, except for cytarabine, cladribine,
vincristine, mercaptopurine and thioguanine. A combined in
vitro drug resistance profile to fludarabine, treosulfan and
mitoxantrone (FTM score) was defined and it had an
independent prognostic significance for disease free survival
in pediatric AML. Conclusion: The combined fludarabine,
treosulfan and mitoxantrone resistance profile to possibly
may be used for better stratification of children with AML or
indicate the necessity for additional therapy.
The response to therapy in childhood acute myeloid
leukemia (AML) is much worse than in acute lymphoblastic
leukemia (ALL). In contrast to ALL, optimal risk-group
stratification so far has not been achieved in childhood AML
(1, 2). Favorable cytogenetics and early response to therapy
are regarded as the most important prognostic factors,
however their value is still limited (3-8). Unlike ALL (9-11),
the role of cellular drug resistance in childhood AML has not
yet been established. Several groups reported possible the
prognostic value of in vitro drug sensitivity in pediatric
AML, showing a good correlation between in vitro drug
resistance and short-term clinical outcome after
chemotherapy (12-16). These findings were related mainly
to cytarabine (15) and cyclophosphamide (16). Part of these
studies included both children and adults. Recently published
large studies showed no correlation between in vitro drug
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resistance to individual drugs and long-term clinical outcome
in childhood AML (17-19). So far, no data exist to support
the prognostic value of any in vitro drug resistance profile in
childhood AML, while this relationship has been confirmed
in adult AML (20). In our previous report, we showed the
possible prognostic value of a combined fludarabine,
treosulfan and etoposide resistance profile to in a subgroup
of children with AML undergoing hematopoietic stem cell
transplantation (21).
We conducted a study to compare the response to therapy
with the drug resistance profile in a large group of children
with AML by evaluating the in vitro sensitivity profile based
on a combination of chemosensitivity to different drugs.
Patients and Methods
Patients. A total of 90 children aged 0.1-17.8 years (median 9.3
years), with de novo AML were initially included in the study. The
median value of their initial white blood cell count was 16.5×109/L
(range, 0.5-516×109/L) in this group. French-American-British
(FAB) morphology was diagnosed as: M0 in 6 children, M1 in 16,
M2 in 24, M3 in 12, M4 in 15, M5 in 10, M6 in 5 and M7 in 2
patients. All patients were treated according to the AML-PPLLSG-
98 protocol of the Polish Pediatric Leukemia and Lymphoma Study
Group (6). Patients with secondary AML, Down syndrome,
biphenotypic leukaemia or death before treatment were not included
in the study. The study was approved by the local Ethics Committee
and written informed consent was obtained from all patients and
their parents.
Drugs. Drug resistance profiling was carried out using the 3-4,5-
dimethylthiazol-2-yl-2,5-difenyl tetrazolium bromide (MTT) assay
for 3-30 drugs for each patient. The following drugs and
concentrations were used: prednisolone (Jelfa, Jelenia Gora, Poland;
concentration range 0.02-694 μM), dexamethasone (Jelfa; 0.5
nM-15.3 μM), daunorubicin (Daunorubicin; Rhone-Poulenc-Rhorer,
Paris; 0.002-3.5 μM), doxorubicin (Doxorubicin; Farmitalia, Milan;
0.01-13.8 μM), idarubicin (Zavedos; Pharmacia & Upjohn, Milan;
0.003-3.7 μM), epirubicin (Farmorubicin; Farmitalia, Milan; 0.003-
3.4 μM), mitoxantrone (Mitoxantrone; Jelfa; 0.002-1.9 μM),
L-asparaginase (Medac, Hamburg, Germany; 0.0032–10 IU/L),
vincristine (Oncovin; Eli-Lilly, Indianapolis, IN, USA; 0.02-21 μM),
vindesine (Eli-Lilly; 0.03-30 μM), etoposide (Vepeside; Bristol-
Myers Squibb, Princeton, NJ, USA; 0.08-85 μM), teniposide
(Vumon; Bristol-Myers Squibb; 0.01-10 μM), 6-mercaptopurine
(M7000; Sigma; St Louis, MO; 91-2937 μM), 6-thioguanine
(A4882; sigma; 9.3-299 μM), cytarabine (Cytosar; Pharmacia &
Upjohn, Bentley, Australia; 0.04-41 μM), fludarabine phosphate
(Fludara; Schering AG, Berlin, Germany; 0.05-54 μM), cladribine
(Biodribin; Bioton, Warsaw, Poland; 0.001-140 μM), 4-HOO-
cyclophosphamide (Asta Medica AG, Frankfurt/Main; 0.3-341 μM),
4-HOO-ifosfamide (Asta Medica AG; 0.3-341 μM), glufosfamide
(Asta Medica AG; 0.5-522 μM), mafosfamide (Asta Medica AG; 0.19-
200 μM), melphalan (Glaxo Wellcome, Parma, Italy; 0.12-131 μM),
thiotepa (Thiotepa; Lederle, Riemser, Greifswald, Germany; 0.16-528
μM), treosulfan (Ovastat; Medac; 0.002-3.6 μM), actinomycin D
(Cosmogen, Merck Sharp & Dohme, Vienna, Austria; 0.03 nM-4 μM),
cisplatin (Platidam; Pliva-Lachema, Brno, Czech Republic;
0.33-333 μM), carboplatin (Cycloplatin; Pliva-Lachema, Brno,
Czech Republic; 1.34-1346 μM), pactitaxel (Taxol; Bristol-Myers
Squibb; 0.05–58 μM), docetaxel (Taxotere; Rhone-Poulenc Rorer,
Antony, France; 0.0001-12 μM), mitomycin C (Mitomycin; Kyowa
Hakko, Tokyo; 0.03-30 μg/ml).
In vitro drug resistance profile. Leukemic cells were separated on a
Ficoll gradient and washed twice with RPMI-1640. The viability,
recovery, cell morphology and percentage of blasts were analysed
before and after the assay. Only samples with at least of 70% of
myeloblasts which successfully tested for at least 3 drugs were
included in the study. Cytotoxicity of tested compounds to leukemic
cells was measured in duplicates by the MTT assay, as described
elsewhere (21, 22). The cytotoxicity was expressed as the LC 50,
the concentration lethal to 50% of the cells.
According to the median cytotoxicity for each of the tested
drugs, all patients were scored as sensitive (score 1) or resistant
(score 2) to this drug. Reference values for the combined in vitro
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Table I. Univariate risk factor analysis for pLFS.

























Early BM response 0.013
Yes 68 0.76±0.07
No 20 0.54±0.13






*Favorable blast karyotype was determined by t(8;21), t(15;17) or
inv(16). FAB: French-American-British morphology classification;
WBC: White blood cell count; BM: bone marrow; FTM: fludarabine,
treosulfan and mitoxantrone.
resistance profile for fludarabine, treosulfan and mitoxantrone
(FTM score) were determined based on the division of all LC 50
values into two equal groups based on the cut-off values created
by the median. All patients were retrospectively re-assessed
based on the results obtained over the whole group. The FTM
score was defined as the sum of the three respective score values
for fludarabine, treosulfan and mitoxantrone, thus FTM score
ranged from 3 to 6. A sensitive FTM profile was regarded as a
score of 3-4, while resistant as 5-6. Results were compared
between groups of children with leukemia subtypes. The relative
resistance (RR) between groups of patients for each drug was
calculated as a ratio of median values of the LC 50 for this drug
in both groups.
Definitions. Complete remission (CR) was defined as no more than
5% blasts in bone amrrow (BM) aspirate with signs of regeneration
of normal hematopoiesis, no blasts in the peripheral blood and the
disappearance of any extramedullary sites. The results were
expressed by means of leukemia-free survival (LFS), calculated
from the date of achieving remission to that of the last follow-up,
relapse or second malignancy. Nonresponders were classified as
LFS=0. Patients undergoing hematopoietic stem cell transplantation
were censored at the time of transplantation.
Statistical analysis. The Mann-Whitney U-test was used for
unpaired comparisons. Survival curves were calculated by the
Kaplan-Meier method and compared by log-rank test. Patients
who received stem cell transplantation were censored at the time
of transplantation. The Cox proportional hazards regression
model was used to test for correlation of each potential
prognostic factor with survival in univariate analysis. The factors
significantly important (shown in Table I) were fitted together in
multivariate analysis in a backward stepwise manner using the
likelihood ratio test until all factors in the model were
significant. All reported p-values are two-sided; p<0.05 was
considered as statistically significant.
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Figure 1. Survival data for risk factors. A, Overall survival; B, probability of leukemia free survival (pLFS) by cytogenetics; C, pLFS by bone marrow
(BM) response by day 28; D, pLFS by combined in vitro resistance profile to fludarabine, treosulfan and mitoxantrone (FTM score).
Results
The probability of overall survival for the whole group was
0.57±0.05, while pLFS=0.58±0.06, and mean survival was
3.36 years (95% confidence interval (CI)=2.95-3.77).
Children who relapsed during follow-up exhibited a non-
significant higher median in vitro resistance of leukemic blasts
to most of the drugs tested, except for cytarabine, cladribine,
vincristine, mercaptopurine and thioguanine. pLFS was not
significantly better in patients with myeloblasts sensitive in
vitro to 4-HOO-cyclophosphamide (0.83±0.15 vs. 0.65±0.09,
p=0.12), doxorubicin (0.81±0.12 vs. 0.64±0.09, p=0.18),
epirubicin (0.72±0.13 vs. 0.61±0.12, p=0.26), fludarabine
(0.73±0.12 vs. 0.62±0.11, p=0.22), mitoxantrone (0.77±0.12
vs. 0.51±0.13, p=0.07), treosulfan (0.88±0.12 vs. 0.62±0.11,
p=0.29), and etoposide (0.70±0.13 vs. 0.63±0.09, p=0.4).
A combined in vitro fludarabine, treosulfan and
mitoxantrone resistance profile (FTM score) proved to be
discriminative for children with AML in univariate analysis
of pLFS: patients with leukemic cells classified as sensitive
according to their FTM score had a significantly better pLFS
than those with myeloblasts resistant to fludarabine,
treosulfan and mitoxantrone (0.73±0.12 vs. 0.50±0.14,
p=0.034) (Figure 1). The results of other risk factors are
shown in Table I. Factors significant by univariate analysis
were fitted together in a Cox model of multivariate analysis.
Two factors showed prognostic value: early BM response by
day 15 (p=0.021; HR=0.29, 95% CI=0.13-0.64) and
myeloblast sensitivity as determined by the combined in vitro
fludarabine, treosulfan and mitoxantrone resistance profile
(FTM score), p=0.048; HR=0.38, 95% CI=0.14-0.97.
Discussion
One of the key factors in success of antileukemic therapy is
related to significant progress in stratification and risk-
adapted therapy. Growing evidence supports the thesis of the
prognostic significance of the in vitro drug resistance profile
in childhood ALL (9, 10, 23), but no relevant data have been
obtained in pediatric AML to date. Early reports have
suggested the putative prognostic role of in vitro resistance to
cytarabine (15), but these data were not confirmed in
subsequent analyses. We have shown in this study that the
combined in vitro fludarabine, treosulfan and mitoxantrone
resistance profile has a strong prognostic significance in
childhood AML. We have shown the impact of the in vitro
drug resistance of 3 agents belonging to 3 different classes
of drugs: the nucleoside analogue fludarabine, the
topoisomerase II inhibitor mitoxantrone and the alkylating
agent treosulfan. These three groups of drugs play a key role
in the therapy of childhood AML, however fludarabine,
treosulfan and mitoxantrone are relatively rarely used in
clinical practice in pediatric oncology.
Drug resistance profiles identified patients at higher risk of
treatment failures. The combined in vitro drug resistance
profile was one of the strongest prognostic factors in a
multivariate analysis for AML of children. No firm
suggestions regarding the use of fludarabine, treosulfan and
mitoxantrone in the treatment of AML can be drawn from our
study, however these results might indicate that patients
whose myeloblasts were sensitive to fludarabine, treosulfan
and mitoxantrone would possibly benefit from the use of
these drugs during the early stages of therapy. Patients
resistant to these drugs should be considered as a high-risk
group or given tailored therapy (24). In spite of the
prognostic significance of ex vivo cytotoxicity results,
cytogenetics of myeloblasts still has a very strong predictive
value in pediatric AML (25).
In conclusion, the in vitro combined fludarabine,
treosulfan and mitoxantrone resistance profile to is of
predictive value in childhood AML. Therefore, the drug
resistance profile may be used for better stratification of
children with AML to prevent overtreatment of those patients
who may be cured by relatively mild chemotherapy and to
identify those patients who are at high risk of treatment
failure and who, therefore, may benefit from more intensive
treatment at initial diagnosis.
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